drugset
Drugs / rcAd26.MOS1.HIV-Env
last change Nov 2018 re-read 3 minutes ago

rcAd26.MOS1.HIV-Env

also known as rcAd26

Vaccine

Developed for
HIV infectious disease
Investigated by
Beth Israel Deaconess Medical Center · International AIDS Vaccine Initiative · University of Rochester

Trials 1

today NCT02366013 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02366013 Jan 2015 → Jun 2016 HIV infectious disease International AIDS Vaccine Initiative Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as rcAd26.MOS1.HIV-Env ClinicalTrials.gov intervention name — accepted as the source's own label NCT02366013 ↗
Known as rcAd26 “We recently developed a replication-competent, highly attenuated Ad26 vector that expresses mosaic HIV-1 Env (rcAd26.MOS1.HIV-Env, "rcAd26").” PMID 30427829 ↗ Nov 2018
Modality Vaccine “an oral, replicating adenovirus 26 vector vaccine” NCT02366013 ↗
Route Oral “The vaccine will be administered orally at a single time point (Day 0)” NCT02366013 ↗